Citations

Clear

76 citation(s) found for "Gore, Steven".

Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
Zeidan, Amer M. , Lee, Ju‐Whei, Prébet, Thomas , Greenberg, Peter L. , Sun, Zhuoxin , Juckett, Mark, Smith, Mitchell R. , Paietta, Elisabeth , Gabrilove, Janice , Katterling, Rhett P., Tallman, Martin S. , Gore, Steven D. , Lee, Ju‐Whei , Erba, Harry Paul , Prebet, Thomas , Zeidan, Amer M

Mayo Clinic

British Journal of Haematology | July 4, 2014 | Volume: 167 | Issue: 1 | Pages: 62-68

10.1111/bjh.13008 | PMID 24995683 Get It

SummaryReliable clinical or molecular predictors of benefit from azacitidine therapy in patients with myelodysplastic syndromes (MDS) are not defined. Doubling of platelet count at start of second cycle of azacitidine therapy compared to baseline was associated with achieving response and survival advantage in a Dutch cohort. To validate this observation, we analysed a larger cohort of North American patients, whose data was collected in a prospective clinical trial with a longer median follow‐up. We found a significant association between platelet count doubling after first cycle of azacitidine therapy and probability of achieving objective response. Among patients with MDS or oligoblastic acute myeloid leukaemia (<30% bone marrow blasts, n = 102), there was a statistically significant reduction in risk of death for patients who achieved platelet count doubling (n = 23, median OS, 21·0 months) compared to those who did not (n = 79, median OS, 16·7 months, adjusted hazard ratio (no/yes)=1·88, 95% confidence interval, 1·03–3·40, P = 0·04). Nonetheless, the addition of this platelet count doubling variable did not improve the survival prediction provided by the revised International Prognostic Scoring System or the French Prognostic Scoring System. Identification of reliable and consistent predictors for clinical benefit for azacitidine therapy remains an unmet medical need and a top research priority.
Sustained remission in a patient with myelodysplastic syndrome and a complex karyotype after erythropoiesis-stimulating therapy followed by colonic T-cell lymphoblastic lymphoma
Zeidan, Amer M. , Faltas, Bishoy M. , Fricke, William, Gore, Steven D. , Ketterling, Rhett P. , Sham, Ronald L., Ketterling, Rhett P , Zeidan, Amer M

Mayo Clinic

Leukemia & Lymphoma | October 25, 2012 | Volume: 54 | Issue: 7 | Pages: 1534-1537

10.3109/10428194.2012.742526 | PMID 23098263 Get It

Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias
Karp, Judith E. , Thomas, B M , Greer, Jacqueline M., Sorge, Christopher L., Gore, Steven D. , Pratz, Keith W. , Flatten, Karen S., Peterson, Kevin, Schneider, Paula A., Mackey, Karen, Freshwater, Tomoko, McDevitt, Michael A. , Gladstone, Douglas E. , Showel, Margaret M. , Loechner, Sabine, Horowitz, Jo Ann, Isaacs, Randi , Smith, B. Douglas , Levis, Mark J. , Carraway, Hetty E. , Parry, David , Kaufmann, Scott H.

Mayo Clinic

Clinical Cancer Research | October 24, 2012 | Volume: 18 | Issue: 24 | Pages: 6723-6731

10.1158/1078-0432.ccr-12-2442 | PMID 23092873 Get It

Abstract Purpose: Incorporation of cytarabine into DNA activates checkpoint kinase 1 (Chk1), which stabilizes stalled replication forks, induces S-phase slowing, and diminishes cytarabine cytotoxicity. The selective Chk1 inhibitor SCH 900776 abrogates cytarabine-induced S-phase arrest and enhances cytarabine cytotoxicity in acute leukemia cell lines and leukemic blasts in vitro. To extend these findings to the clinical setting, we have conducted a phase I study of cytarabine and SCH 900776. Experimental Design: Twenty-four adults with relapsed and refractory acute leukemias received timed sequential, continuous infusion cytarabine 2 g/m2 over 72 hours (667 mg/m2/24 hours) beginning on day 1 and again on day 10. SCH 900776 was administered as a 15- to 30-minute infusion on days 2, 3, 11, and 12. The starting dose of SCH 900776 was 10 mg/m2/dose. Results: Dose-limiting toxicities consisting of corrected QT interval prolongation and grade 3 palmar-plantar erythrodysesthesia occurred at 140 mg flat dosing (dose level 5, equivalent to 80 mg/m2). Complete remissions occurred in 8 of 24 (33%) patients, with 7 of 8 at 40 mg/m2 or higher. SCH 900776 did not accumulate at any dose level. Marrow blasts obtained pretreatment and during therapy showed increased phosphorylation of H2Ax after SCH 900776 beginning at 40 mg/m2, consistent with unrepaired DNA damage. Conclusions: These data support a randomized phase II trial of cytarabine +/− SCH 900776 at a recommended flat dose of 100 mg (equivalent to 56 mg/m2) for adults with poor-risk leukemias. The trial (SP P05247) was registered at www.clinicaltrials.gov as NCT00907517. Clin Cancer Res; 18(24); 6723–31. ©2012 AACR.
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia
Karp, Judith E. , Vener, Tatiana, Raponi, Mitch , Ritchie, Ellen K. , Gore, Steven D. , Morris, Lawrence E. , Feldman, Eric J. , Greer, Jacqueline M., Malek, Sami N. , Ironside, Valerie, Galkin, Steven, McDevitt, Michael A. , Roboz, G., Gocke, Christopher D. , Derecho, Carlo, Palma, John F. , Wright, John J., Garret-Mayer, Elizabeth, Smith, Benjamin D. , Carraway, Hetty E. , Levis, Mark J. , Roboz, Gail J. , Wang, Yixin , Kaufmann, Scott H. , Wright, John J.

Mayo Clinic

Blood | October 15, 2011 | Volume: 119 | Issue: 1 | Pages: 55-63

10.1182/blood-2011-08-370825 | PMID 22001391 Get It

Abstract Tipifarnib (T) exhibits modest activity in elderly adults with newly diagnosed acute myelogenous leukemia (AML). Based on preclinical synergy, a phase 1 trial of T plus etoposide (E) yielded 25% complete remission (CR). We selected 2 comparable dose levels for a randomized phase 2 trial in 84 adults (age range, 70-90 years; median, 76 years) who were not candidates for conventional chemotherapy. Arm A (T 600 mg twice a day × 14 days, E 100 mg days 1-3 and 8-10) and arm B (T 400 mg twice a day × 14 days, E 200 mg days 1-3 and 8-10) yielded similar CR, but arm B had greater toxicity. Total CR was 25%, day 30 death rate 7%. A 2-gene signature of high RASGRP1 and low aprataxin (APTX) expression previously predicted for T response. Assays using blasts from a subset of 40 patients treated with T plus E on this study showed that AMLs with a RASGRP1/APTX ratio of more than 5.2 had a 78% CR rate and negative predictive value 87%. This ratio did not correlate with outcome in 41 patients treated with conventional chemotherapies. The next T-based clinical trials will test the ability of the 2-gene signature to enrich for T responders prospectively. This study is registered at www.clinicaltrials.gov as #NCT00602771.
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide
Karp, Judith E. , Flatten, Karen S., Feldman, Eric J. , Greer, Jacqueline M., Loegering, David A., Ricklis, Rebecca M., Morris, Lawrence E. , Ritchie, Ellen K. , Ironside, Valerie, Talbott, Timothy M., Le, Son B. , Meng, Xue , Schneider, Paula A., Dai, Nga T., Adjei, Alex A. , Gore, Steven D. , Wright, John J., Smith, B. Douglas , Roboz, Gail J. , Levis, Mark J. , Wright, John J., Garrett‐Mayer, Elizabeth , Kaufmann, Scott H.

Mayo Clinic

Blood | December 24, 2008 | Volume: 113 | Issue: 20 | Pages: 4841-4852

10.1182/blood-2008-08-172726 | PMID 19109557 Get It

Abstract The farnesyltransferase inhibitor tipifarnib exhibits modest activity against acute myelogenous leukemia. To build on these results, we examined the effect of combining tipifarnib with other agents. Tipifarnib inhibited signaling downstream of the farnesylated small G protein Rheb and synergistically enhanced etoposide-induced antiproliferative effects in lymphohematopoietic cell lines and acute myelogenous leukemia isolates. We subsequently conducted a phase 1 trial of tipifarnib plus etoposide in adults over 70 years of age who were not candidates for conventional therapy. A total of 84 patients (median age, 77 years) received 224 cycles of oral tipifarnib (300-600 mg twice daily for 14 or 21 days) plus oral etoposide (100-200 mg daily on days 1-3 and 8-10). Dose-limiting toxicities occurred with 21-day tipifarnib. Complete remissions were achieved in 16 of 54 (30%) receiving 14-day tipifarnib versus 5 of 30 (17%) receiving 21-day tipifarnib. Complete remissions occurred in 50% of two 14-day tipifarnib cohorts: 3A (tipifarnib 600, etoposide 100) and 8A (tipifarnib 400, etoposide 200). In vivo, tipifarnib plus etoposide decreased ribosomal S6 protein phosphorylation and increased histone H2AX phosphorylation and apoptosis. Tipifarnib plus etoposide is a promising orally bioavailable regimen that warrants further evaluation in elderly adults who are not candidates for conventional induction chemotherapy. These clinical studies are registered at www.clinicaltrials.gov as #NCT00112853.
Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-β-d-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias
Karp, Judith E. , Passaniti, Antonino , Gojo, Ivana , Kaufmann, Scott H. , Bible, Keith C. , Garimella, Τushar , Greer, Jacqueline M., Briel, Janet, Gore, Steven D. , Tidwell, Michael L., Ross, Douglas D., Wright, John J., Bauer, Kenneth S., Smith, B. Douglas , Wright, John J., Colevas, Alexander Dimitrios , Kaufmann, Scott H

Mayo Clinic

Clinical Cancer Research | March 21, 2006 | Volume: 11 | Issue: 23 | Pages: 8403-8412

10.1158/1078-0432.ccr-05-1201 | PMID 16322302 Get It

Abstract Purpose: The serine/threonine kinase inhibitor flavopiridol targets multiple cyclin-dependent kinases, induces checkpoint arrest, and interrupts transcriptional elongation. We designed a phase I clinical trial using a timed sequential therapy approach where flavopiridol was given for the dual purpose of initial cytoreduction and enhancing cell cycle progression of the remaining leukemia cell cohort followed by cycle-dependent drugs 1-β-d-arabinofuranosylcytosine (ara-C) and mitoxantrone. Experimental Design: Flavopiridol was given by 1-hour infusion daily for 3 days beginning day 1 followed by 2 g/m2/72 h ara-C beginning day 6 and 40 mg/m2 mitoxantrone beginning day 9. In vivo correlates included pharmacokinetics, modulation of blast cycle regulators, and serum and marrow supernatant vascular endothelial growth factor levels. Results: Of 34 adults receiving induction therapy, 16 (47%) evinced direct leukemia cytotoxicity with ≥50% drop in peripheral blast counts and tumor lysis in 9 (26%). Four (12%) died during therapy (two fungal infections and two sudden death). Dose-limiting toxicity occurred at 60 mg/m2/d with profound neutropenia &gt;40 days duration, and maximal tolerated dose was 50 mg/m2/d. Overall response rate was 31% in 26 acute myelogenous leukemia and 12.5% in acute lymphoblastic leukemia. Pharmacokinetics showed that a linear two-compartment model with first-order elimination provided the best fit of the observed concentration versus time data. Flavopiridol down-regulated one or more target proteins in marrow blasts in vivo. Vascular endothelial growth factor was detected in sera and marrow supernatant pretreatment, and sera obtained on day 3 inhibited bovine aortic endothelial cell proliferation by a mean of 32% (range, 10-80%). Conclusions: Our data suggest that flavopiridol is cytotoxic to leukemic cells and, when followed by ara-C and mitoxantrone, exerts biological and clinical effects in patients with relapsed and refractory acute leukemias. These findings warrant continuing development of flavopiridol at 50 mg/m2/d × 3 days in combination with cytotoxic and biological agents for acute leukemias.